Oct 28, 2026 earnings call — Appellis acquisition boosts growth portfolio
Biogen reported total revenue of $2.8 billion, up 11% year over year, driven by Appellis and strong growth-product sales.
Revenue $2.8B (est $2.6B) · EPS $2.62 (est $1.99)
Key quotes
"we are on track to realize $250 million of run rate synergies by the end of 27."
"Starting with our plan disclosure of the 2 phase 3 SLE studies for litifilumab in the first half of December."
"The portfolio now represents approximately 63% of our total core pharmaceutical revenue."
Analyst Q&A 15
litifilimab Phase III confidence
Q (Phil Nadeau · TD Cowen): Analyst asked Biogen's confidence that Phase III litifilimab trials in SLE will succeed and differences from Phase II.
A: Management said lupus is heterogeneous and they have strategies to optimize outcomes, like steroid tapering and background med control. They noted no new changes and said both readouts will be disclosed in the first half of December.
"So I think just stepping back, we recognize and lupus is a very heterogeneous disease." — Priya Singhal
felzartamab commercial ramp
Q (Chris Schott · JPMorgan): Analyst asked how Biogen is thinking about market development and ramp for felzartamab in AMR and how Street models the opportunity.
A: Management described physician enthusiasm at transplant centers and said about 11 thousand AMR patients exist but not all will be treated. They said launch will get an initial bolus from transplant centers, protocols take time, they have a medical team visiting centers, and MVI adds about 30% incremental patients.
"When you look at AMR, we believe there is around 11 thousand patients." — Alisha Alaimo (PRESIDENT)
baseline IFN gene signature
Q (Brian Abrahams · RBC): Analyst asked how baseline interferon gene signatures in TOPAZ 1 and 2 compare to phase 2 for litifilimab.
A: Management expects interferon gene signature to be high in SLE and said literature supports that. They said they are not aware of baseline differences between Lilac and TOPAZ 1 and 2 and will only know after looking at the data.
"I think interferon gene signature across the board, we expect it to be high." — Priya Singhal
SRI-4 driver in Phase II vs III
Q (Umer Raffat · Evercore): Analyst asked whether SLE Phase III will see SLEDAI-2K driving SRI-4 like in Phase II, and about pooling by interferon-high subgroup.
A: Management said SRI-4 was the right primary endpoint because focus is on skin and joints. They said they will decide about pooling or combining trials after seeing data and in consultation with regulators; approaches will be data dependent.
"I think we will have the opportunity once we see the data to decide how we might pool and what aspects of these trials should be combined." — Priya Singhal
SYFOVRE injection growth reasons
Q (Salveen Richter · Goldman Sachs): Analyst asked how much SYFOVRE injection increase is from reducing free drug versus demand and what education improves discontinuation.
A: Management said lowering free goods contributed and the team improved sentiment about treating GA so more HCPs are prescribing and patients are willing to get injections. They said high drop-off after first month is due to patients expecting immediate visible results, so they plan education for patients, office staff, physicians and plan DTC next year.
"The team has done actually a phenomenal job with lowering the free goods on this product, but that is been throughout ever since we did the acquisition." — Alisha Alaimo (PRESIDENT)
cutaneous lupus readout confidence
Q (Michael Yee · UBS): Analyst asked Biogen's confidence in the cutaneous lupus (CLE) readout versus systemic SLE.
A: Management said both SLE and CLE are high unmet need and that Phase II showed activity in both. They declined to speculate on confidence, noted systemic lupus is more heterogeneous, and said CLE is visible so impact is easier to assess; they will wait for Phase III data.
"I am not gonna really talk about confidence." — Priya Singhal
SPINRAZA high dose adoption
Q (Alex Hammond · Wolfe): Analyst asked conversion levels in US for SPINRAZA high dose and whether it supports commercial dynamics for salinersen.
A: Management said SPINRAZA high dose launch set a new benchmark and community demand pulled physicians to request it globally. They reported 70% of 12 mg patients have a start form and 50% have been dosed by end of Q3, noted switchbacks and timing around Zolgensma, and said goal is to maintain patients ahead of potential salinersen launch.
"At the end of Q3, 70% of the 12 mg patients now have a start form submitted, which is very high." — Alisha Alaimo (PRESIDENT)
ZURZUVAE pricing case outside US
Q (Paul Matteis · Stifel): Analyst asked work done to justify premium pricing for ZURZUVAE outside US and role of cognition effects.
A: Management said there is opportunity to reprice the market if phase 3 replicates Phase II cognitive benefit. They said that would create a compelling proposition to present to payers in Europe, but they still need to see the phase 3 results.
"Yeah. Paul, I think the, there is an opportunity to reprice this market, and the real differentiation is the impact on cognition as you said." — Christopher A. Viehbacher (CEO)
LEQEMBI iClick impact
Q (Evan Seigerman · BMO): Analyst asked feedback from patients and providers on LEQEMBI iClick and whether it drives uptake and how to expand next year.
A: Management said Part D coverage is at least 50% now and likely to grow; enrollment is in flux during open enrollment. They said iClick reframes convenience, is outpacing IV launches, is driving new prescribers including clinicians who had not written AATs, and they view it as a tool to grow the overall market.
"I think that what you are gonna see is it is re. Really reframing the convenience conversation." — Alisha Alaimo (PRESIDENT)
capital allocation priorities
Q (Geoffrey Meacham · Citi): Analyst asked what Biogen would prioritize for capital deployment: expand felzartamab, commercial investment, SYFOVRE, or BD.
A: Management said they will invest in commercial and R&D while being mindful of profitability and not overextending. They prefer early-stage BD (DC to Phase 1b), said Appellis gave a commercial team for felzartamab, lupus will need significant investment and education, and they will be opportunistic in M&A while avoiding distraction.
"I really always hated having to go buy assets in later stage because there is still a fair amount of risk associated with that." — Christopher A. Viehbacher (CEO)
sizing CLE vs SLE opportunity
Q (David Amsellem · Piper Sandler): Analyst asked how Biogen sizes CLE relative to SLE and how distinct the opportunities are commercially.
A: Management said they view CLE and SLE as separate markets with CLE totaling 300 thousand patients (250 thousand CLE only plus 50 thousand both) and SLE 300 thousand SLE only. They said CLE is under-treated (<5% treated) versus SLE (~30%), dermatology will need patient services and simple access, and dermatologists may adopt once they see safety, efficacy, and formulary access.
"So if you look at CLE, there is 250 thousand patients that have CLE only." — Alisha Alaimo (PRESIDENT)
IgAN endpoint change to eGFR
Q (Danielle Brill · Truist): Analyst asked if FDA openness to 1-year eGFR endpoint leads to reconsidering PREVAIL design and adequacy of power.
A: Management said they will update the primary endpoint to eGFR to reflect evolving evidence and regulatory expectations because eGFR is a more clinically meaningful long-term kidney measure. They also emphasized the importance of drug holiday and remission off-drug as a differentiator and will keep both aspects in mind.
"We are planning to stay current and ahead by updating our primary endpoint to eGFR to reflect the evolving evidence base and the increasing importance of directly assessing kidney function and IgAN." — Priya Singhal
guidance and Q4 drop concern
Q (Mohit Bansal · Wells Fargo): Analyst asked why guidance implies a large sequential drop from Q3 to Q4 and what is being missed in the math.
A: Management said Q3 had a pull-forward from SPINRAZA high dose conversions and some inventory dynamics, creating a top-line tailwind. The guidance raise reflects Appellis integration, top-line performance, and earlier capture of synergies on the expense side.
"So when you look at the Q3 results, as I noted in my remarks, on a top line basis, we noted that we did have this significant tailwind." — Robin C. Kramer (CFO)
positioning if two SLE drugs succeed
Q (Jefferies): Analyst asked how litifilimab and dapirolizumab would be positioned relative to each other and as potential first-line SLE therapies.
A: Management said they are working on positioning and view having two shots on goal as important; the products may differentiate (e.g., dapirolizumab showed fatigue improvement). They said success will be data dependent and also depend on addressing barriers to prescribing and patient activation; commercialization strategy will be important.
"So we are working on positioning right now for both of these products." — Alisha Alaimo (PRESIDENT)
SKYCLARYS patient growth and geography
Q (Marc Goodman · Leerink Partners): Analyst asked for detail on SKYCLARYS patient growth in the U.S. and dynamics overseas by country, reimbursement, and launches.
A: Management said U.S. growth is encouraged by patient-finding tools and AI, and discount rates have normalized to lower levels yielding continued year-over-year growth; pediatric expansion is the next meaningful opportunity. For ex-US, management said future growth will come from global SKYCLARYS expansion and new jurisdiction launches, including recent approval in Brazil.
"We expect from a demand perspective, that the growth on both the remainder of this year and into next year is primarily going to be coming from the continued expansion of SKYCLARYS globally." — Robin C. Kramer (CFO)